Can-Fite BioPharma (CANF) Income from Non-Controlling Interests (2015 - 2017)

Can-Fite BioPharma's (CANF) quarterly Income from Non-Controlling Interests came in at $59000.0 in Q1 2015.

Can-Fite BioPharma (CANF) Income from Non-Controlling Interests (2015 - 2017) Analysis & Trends

Can-Fite BioPharma (CANF) has 1 years of Income from Non-Controlling Interests data on file, last reported at $59000.0 in Q1 2015.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Inc. Minority (Qtr)
1	Vertex Pharmaceuticals	139.13 Bn	131.28 Bn	2.84 Bn	-
2	Regeneron Pharmaceuticals	85.77 Bn	77.77 Bn	3.93 Bn	-
3	Argenx Se	64.64 Bn	59.46 Bn	1.37 Bn	-
4	Moderna	58.29 Bn	53.16 Bn	52.00 Mn	-
5	BeOne Medicines	41.92 Bn	36.82 Bn	1.53 Bn	-
6	Alnylam Pharmaceuticals	31.58 Bn	28.28 Bn	992.69 Mn	-
7	BioNTech SE	28.12 Bn	9.73 Bn	668.28 Mn	-
8	Insmed	27.39 Bn	26.22 Bn	358.27 Mn	-
9	Royalty Pharma	27.27 Bn	26.43 Bn	-	63.60 Mn
10	Can-Fite BioPharma	2.76 Mn	-8.79 Mn	-	-

Download Data